Eli Lilly acquires cancer program from Scorpion Therapeutics

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion.
Lilly pads cancer drug pipeline with Scorpion deal
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire Scorpion's experimental oral therapy,
Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha
Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn
Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion
Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront payment and subsequent amounts that Scorpion's shareholders would receive as certain regulatory and sales milestones are achieved.
Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash
Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor
Eli Lilly to acquire Scorpion for up to $2.5B
Eli Lilly (NYSE:LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity focused on precision medicine. Scorpion's lead drug asset,
How the scorpion lollipop became an Arizona icon — even though it's not made here
Ever wondered how gem-like lollipops with a scorpion inside are made? Here's how and why they've become so popular in Arizona ...
4,100-year-old Egyptian tomb belongs to royal courtier with unique life-saving skill
Swiss-French archaeologists have uncovered the 4,100-year-old tomb in Egypt that belonged to a royal physician with a very ...
TransMedics says claims made by Scorpion Capital ‘have no merit’
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
Discover Magazine8h
Rats Facing Lego Robot Scorpions May Help Understand Human Anxiety
Recording neuron activity associated with different objects can show how nervousness related to specific locations or objects ...
Why TransMedics Group Stock Is Tanking Today
Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...
Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says
Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...
Rumored Spider-Man 4 Villains Would Bring Fan Favorite Characters To The MCU
Lisa Kudrow revealed during an interview on “The Drew Barrymore Show” (via People) that she recently discovered a note the ...